Esther I Verhoef

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3704607/publications.pdf

Version: 2024-02-01

33 papers	1,125 citations	430874 18 h-index	395702 33 g-index
34 all docs	34 docs citations	34 times ranked	1774 citing authors

#	Article	IF	Citations
1	Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Modern Pathology, 2016, 29, 630-636.	5.5	174
2	A Prostate Cancer â€œ Nimbosus â€ : Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology, 2017, 72, 665-674.	1.9	142
3	Threeâ€dimensional microscopic analysis of clinical prostate specimens. Histopathology, 2016, 69, 985-992.	2.9	71
4	Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Modern Pathology, 2019, 32, 139-146.	5.5	71
5	Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. European Journal of Cancer, 2016, 66, 26-33.	2.8	66
6	SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer. Cancer Research, 2015, 75, 230-240.	0.9	61
7	Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. European Urology, 2020, 77, 191-198.	1.9	57
8	Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget, 2015, 6, 4036-4050.	1.8	42
9	Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Oncotarget, 2015, 6, 24488-24498.	1.8	42
10	Epithelialâ€“Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression. Cancer Research, 2018, 78, 4671-4679.	0.9	41
11	Validation of stem cell markers in clinical prostate cancer: Î±6-Integrin is predictive for non-aggressive disease. Prostate, 2014, 74, 488-496.	2.3	37
12	Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Modern Pathology, 2021, 34, 184-193.	5.5	32
13	Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. Modern Pathology, 2019, 32, 1032-1041.	5.5	30
14	Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading. Histopathology, 2020, 77, 850-861.	2.9	24
15	Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology, 2019, 75, 338-345.	2.9	22
16	Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. Oncotarget, 2016, 7, 70669-70684.	1.8	21
17	Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy. American Journal of Surgical Pathology, 2020, 44, 191-197.	3.7	20
18	Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. Histopathology, 2020, 76, 755-762.	2.9	18

#	Article	IF	Citations
19	MET expression during prostate cancer progression. Oncotarget, 2016, 7, 31029-31036.	1.8	18
20	PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Endocrine-Related Cancer, 2019, 26, 471-482.	3.1	17
21	Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3Â+Â4Â=Â7 and highest Gleason score 3Â+Â4Â=Â7 or >Â3Â+Â4Â=Â7. Histopathology, 2018, 72, 760-765.	2.9	14
22	Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. Oncotarget, 2016, 7, 13167-13181.	1.8	14
23	Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget, 2016, 7, 37846-37856.	1.8	14
24	Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model. EBioMedicine, 2018, 27, 182-186.	6.1	11
25	Threeâ€dimensional architecture of common benign and precancerous prostate epithelial lesions. Histopathology, 2019, 74, 1036-1044.	2.9	11
26	Clinicopathological characteristics of glomeruloid architecture in prostate cancer. Modern Pathology, 2020, 33, 1618-1625.	5.5	11
27	Differential tissue expression of extracellular vesicleâ€derived proteins in prostate cancer. Prostate, 2019, 79, 1032-1042.	2.3	10
28	Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients. Modern Pathology, 2021, 34, 2064-2070.	5.5	10
29	Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer. Oncotarget, 2018, 9, 36444-36456.	1.8	10
30	APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer. Cancers, 2019, 11, 1062.	3.7	9
31	Combined transmission, dark field and fluorescence microscopy for intact, 3D tissue analysis of biopsies. Journal of Biomedical Optics, 2020, 25, .	2.6	3
32	Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies. Archives of Pathology and Laboratory Medicine, 2020, 144, 991-996.	2.5	1
33	Combined transmission, dark field and fluorescence microscopy for intact, 3D tissue analysis of biopsies. Journal of Biomedical Optics, 2020, 25, .	2.6	1